Safety and effectiveness of long-term growth hormone therapy in Japanese patients with adult growth hormone deficiency: a postmarketing, multicenter, observational study.

What Was Tested

Researchers studied Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in this observational study publication.

Patients' data were obtained from medical records.

Measurements (lipids, glucose metabolism, and body composition) taken at baseline; 3, 6, and 12 months; and yearly until the end of the study were collected.

Who Took Part

The study group was 387 patients.

PubMed indexes the participants as young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

In design terms this was a multicenter study.

Running at several centres spread the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) study over different clinics and patient groups.

Adverse drug reactions (ADRs), serious ADRs, and serious adverse events (SAEs) were evaluated.

What Was Measured

Measurements (lipids, glucose metabolism, and body composition) taken at baseline; 3, 6, and 12 months; and yearly until the end of the study were collected.

The subject headings attached to it are Biomarkers, Congenital Hypothyroidism, Drug Monitoring, Dwarfism, Pituitary, Hormone Replacement Therapy, Human Growth Hormone and Japan.

The authors tagged it with the keywords Growth hormone deficiency, Postmarketing, Safety and Somatropin.

What This Means in Plain Language

The paper is a multicenter study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 387 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2017 (Endocrine journal), a journal based in Japan.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.